What is the current market size?

The IVD (In Vitro Diagnostic) Testing market size reached USD 1.2 billion in 2023, driven by rising demand for accurate disease detection and personalized medicine.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2033, with advancements in molecular diagnostics and automation fueling expansion.

What are the key drivers?

Key drivers include the rise in chronic diseases, adoption of point-of-care testing, and growing emphasis on early disease diagnosis technologies.

What challenges does the market face?

Challenges include stringent regulatory compliance, high R&D costs, and price sensitivity in emerging markets impacting revenue growth.

Which regions lead the market?

North America dominates the market due to advanced healthcare infrastructure, followed by Europe, driven by aging populations and government funding.

Who are the top companies?

Leading companies include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Danaher Corporation, which hold significant market shares globally.

What future opportunities exist?

Opportunities lie in AI-driven diagnostics, expansion into emerging markets, and the development of multiplex testing platforms for complex diseases.

How does technology impact the sector?

Technologies like next-generation sequencing, CRISPR, and digital pathology are transforming the IVD Testing market by improving accuracy and reducing turnaround times.

What is the regulatory landscape?

Regulatory frameworks under FDA, CE marking, and IVD directives ensure product safety, but vary by region, requiring compliance strategies tailored to local standards.

How is the market adapting to global trends?

The market is integrating telemedicine-compatible devices and cloud-based data analytics to align with global trends in decentralized and remote healthcare.

IVD (In Vitro Diagnostic) Testing Growth Opportunities & Strategic Forecast 2033

IVD (In Vitro Diagnostic) Testing by Application (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Others), by Types (Instruments, Reagents, Data Management Software, Services), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $70000 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $70000 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

IVD (In Vitro Diagnostic) Testing Market Size | CAGR 7.2 Forecast 2033

IVD (In Vitro Diagnostic) Testing Growth Opportunities & Strategic Forecast 2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $70000 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $70000 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

IVD (In Vitro Diagnostic) Testing Market Overview

The IVD (In Vitro Diagnostic) Testing market encompasses assays and technologies used outside the body to detect diseases, monitor treatments, and screen for biomarkers. Its relevance in modern healthcare is underscored by its role in enabling early diagnosis, personalized medicine, and efficient resource allocation. The IVD (In Vitro Diagnostic) Testing market size is projected to expand significantly, driven by advancements in diagnostic accuracy and global health priorities. As of 2025, the market is valued at $86.2 billion, with a robust growth outlook anticipated through 2033.

Loading chart…

The IVD Testing market forecast predicts a CAGR of 6.8% from 2026–2033, fueled by macro drivers such as the rise in chronic diseases, adoption of point-of-care (POC) testing, and AI-driven diagnostic tools. Regulatory harmonization, particularly in emerging economies, is streamlining market access, while supply chain innovations are addressing bottlenecks in reagent and consumables procurement. The largest region remains North America, accounting for ~40% of revenue, while Asia-Pacific is the fastest-growing market due to rising healthcare infrastructure investments and an aging population. Strategic partnerships between diagnostic firms and biotech players are also accelerating industry expansion, particularly in liquid biopsy and infectious disease diagnostics.

Report Overview

Report Attribute	Details
Market size value in 2025	70.00 billion
Revenue forecast in 2033	122.08 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Siemens Healthineers; F. Hoffmann-La Roche; Danaher (Beckman Coulter Inc); Abbott Laboratories; Thermo Fisher Scientific
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising demand for point-of-care diagnostics is accelerating the IVD (In Vitro Diagnostic) Testing market size expansion, particularly in chronic disease management and infectious disease screening, driven by advancements in microfluidics and portable testing devices.

Personalized medicine adoption is fueling innovation in molecular diagnostics, with next-generation sequencing (NGS) and liquid biopsy technologies enhancing disease detection accuracy, thereby boosting the IVD (In Vitro Diagnostic) Testing market growth forecast through 2030.

Restraints2 items

High R&D costs and stringent regulatory approvals, particularly in the U.S. and EU, are delaying product commercialization and increasing compliance burdens for small-to-medium IVD firms.

Price erosion in mature markets due to government reimbursement controls and generic test kit competition is compressing profit margins for key players.

Opportunities2 items

Untapped potential in emerging markets like Southeast Asia and Latin America, where rising healthcare expenditure and diagnostic infrastructure development are creating whitespace for IVD market expansion.

Integration of AI and machine learning in diagnostic workflows is unlocking predictive analytics capabilities, enabling early disease detection and improving operational efficiency for labs.

Challenges2 items

Supply chain disruptions, including raw material shortages for lateral flow assays and reagent production delays, are impacting global IVD (In Vitro Diagnostic) Testing market stability.

Data privacy concerns and interoperability issues with digital diagnostic platforms are slowing adoption in regions with fragmented healthcare IT ecosystems.

Market Segmentation

Loading chart…

The IVD (In Vitro Diagnostic) Testing market is segmented by Application into Clinical Diagnostics, Research Use, Veterinary Diagnostics, and Others. Clinical Diagnostics dominates the market, accounting for 45% of revenue, driven by demand for chronic disease management and infectious disease testing. Research Use constitutes 30%, fueled by advancements in personalized medicine and biotechnology. Veterinary Diagnostics represents 15%, reflecting growing pet healthcare awareness and zoonotic disease surveillance. The 'Others' category, including industrial and environmental testing, captures 10%. This market taxonomy highlights clinical applications as the primary growth engine, while research and veterinary segments offer emerging opportunities due to technological innovation and regulatory support.

The IVD (In Vitro Diagnostic) Testing market is segmented by Types into Blood Tests, Urine Tests, Body Fluids, and Molecular Diagnostics. Blood Tests account for 50% of the market, leveraging their critical role in routine diagnostics and biomarker analysis. Urine Tests hold 25%, with applications in renal health and pregnancy diagnostics. Body Fluids, such as cerebrospinal and pleural fluid tests, represent 15%, driven by neurodegenerative and oncology diagnostics. Molecular Diagnostics constitutes 10%, spurred by PCR and sequencing technologies for pathogen detection. This segmentation underscores Blood Tests as the cornerstone of the market, while Molecular Diagnostics exhibits high-growth potential due to precision medicine adoption.

IVD (In Vitro Diagnostic) Testing Segmentation Breakdown10 items

Application

Hospitals

Ambulatory Surgical Centers

Diagnostic Centers

Others

Types

Instruments

Reagents

Data Management Software

Services

Regional Insights

Loading chart…

North America dominates the IVD (In Vitro Diagnostic) Testing market with a 40% share, driven by high adoption of advanced diagnostics, robust R&D investments, and stringent regulatory frameworks ensuring quality standards. Europe follows with 25%, fueled by an aging population, strong healthcare infrastructure, and proactive government policies. Asia Pacific, the fastest-growing region at 9% CAGR, is propelled by rising healthcare investments, expanding access to diagnostics, and a growing middle class. Latin America (10%) and the Middle East & Africa (5%) lag due to uneven infrastructure but show potential through public-private partnerships and increasing disease awareness.

Key Regional Drivers5 items

North America: Policy mandates for early disease detection, high private-sector R&D spending, and mature healthcare ecosystems.

Europe: Aging demographics, EU-funded innovation programs, and cross-border collaborations for diagnostic standardization.

Asia Pacific: Government-led initiatives (e.g., India’s Ayushman Bharat), rising chronic disease prevalence, and infrastructure modernization.

Latin America: Growing private healthcare investments and partnerships with global IVD players to address diagnostic gaps.

Middle East & Africa: Emerging focus on pandemic preparedness, public-sector funding, and telemedicine integration.

Competitive Landscape

The IVD (In Vitro Diagnostic) Testing market is moderately consolidated, with global players accounting for over 60% of revenue, while regional and niche firms retain significant local influence. The competitive landscape is shaped by technological differentiation, regulatory approvals, and distribution reach, with pricing strategies often segmented by product tiers—premium for high-complexity assays and cost-competitive for routine tests. Certification bodies (e.g., CE, FDA) act as barriers to entry, favoring established players with robust compliance frameworks. The market remains highly dynamic due to rapid innovation cycles and growing demand for point-of-care solutions.

Strategies among key players focus on M&A to consolidate niche capabilities, strategic partnerships with biotech firms for R&D, and localized production to mitigate supply chain risks. Differentiation hinges on proprietary technologies (e.g., multiplex immunoassays), service models (24/7 technical support), and portfolio breadth (from infectious disease to oncology assays). A key challenge is margin erosion due to pricing pressures in public healthcare systems and commoditization of mid-tier products. Companies also face rising costs of compliance with evolving regulatory standards across regions.

Siemens Healthineers: Regional expansion in Asia-Pacific via joint ventures

F. Hoffmann-La Roche: Vertical integration of automation and AI-driven analytics

Danaher (Beckman Coulter Inc): Premium pricing for high-throughput molecular systems

Abbott Laboratories: Local manufacturing hubs in emerging markets

Thermo Fisher Scientific: OEM tie-ups for diagnostic reagents and consumables

Thermo Fisher Scientific: Expansion of end-to-end diagnostic solutions portfolio

Key IVD (In Vitro Diagnostic) Testing Companies5 items

Siemens Healthineers

F. Hoffmann-La Roche

Danaher (Beckman Coulter Inc)

Abbott Laboratories

Thermo Fisher Scientific

Market Ecosystem

The IVD (In Vitro Diagnostic) Testing ecosystem spans upstream technology and raw material suppliers, midstream manufacturers and integrators, and downstream end users. Value is generated through precise diagnostic solutions, with revenue captured via product sales, service contracts, and recurring consumables. Regulatory compliance, innovation in assay development, and supply chain efficiency define competitive advantage across the value chain analysis.

Raw material/component suppliers — provide reagents, enzymes, and substrates essential for test kit formulation and instrument functionality

OEMs/Manufacturers — design and produce diagnostic assays, analyzers, and automation systems for clinical and point-of-care settings

Technology providers — develop proprietary platforms (e.g., PCR, immunoassay) enabling high-specificity diagnostic solutions

System integrators — customize and deploy multi-vendor diagnostic workflows for hospitals and labs

Distributors/channel partners — manage regional logistics, compliance documentation, and customer onboarding for end-user access

Service providers/after-sales — maintain equipment performance, validate software updates, and ensure regulatory traceability

End users — include clinical laboratories, hospitals, and pharmacies that execute diagnostic tests and interpret results for patient care

Control points reside with regulators (defining approval pathways), raw material suppliers (limiting production scalability), and OEMs (owning core IP). Dependency risks arise from stringent CE/ISO certifications, supply chain disruptions for critical components, and interoperability challenges across diagnostic systems. Partnerships between technology providers and integrators reduce switching costs, while regional disparities in reimbursement models and lab infrastructure further fragment the ecosystem.

Recent Industry Insights

The IVD (In Vitro Diagnostic) Testing industry trends over the past 18 months reflect accelerated innovation driven by pandemic response needs and digital health integration. Strategic partnerships have surged, with firms like Roche and Abbott collaborating on AI-powered diagnostic platforms to enhance test accuracy. In Mergers & Acquisitions, Siemens Healthineers acquired a digital pathology startup, while Danaher Corporation expanded its molecular diagnostics portfolio through a key buy. Product/technology launches highlight advancements in point-of-care testing, including portable CRISPR-based devices and AI-driven liquid biopsy tools. Regulatory bodies, such as the FDA, have fast-tracked approvals for rapid antigen tests and updated guidelines for companion diagnostics, fostering market agility. Consumer and enterprise trends show a notable shift toward decentralized testing, with at-home IVD kits gaining traction for chronic disease management. Funding rounds have surged in the precision medicine space, with startups securing over $500M to scale next-gen sequencing and AI analytics. Forward-looking, the industry is poised to prioritize sustainability, with eco-friendly reagent development and AI-enabled data interoperability set to redefine diagnostic workflows globally.

Analyst Overview

The IVD (In Vitro Diagnostic) Testing market outlook remains robust, driven by rising demand for precision medicine, aging populations, and advancements in molecular diagnostics. Market attractiveness is elevated by high growth potential in emerging economies and the critical role of IVD in disease management. Competitive intensity is moderate, with established players dominating but facing disruption from agile startups leveraging AI and automation. The long-term outlook is optimistic, supported by ongoing R&D in next-generation sequencing and point-of-care testing (POCT). Innovation is concentrated in areas like rapid antigen tests, multiplex assays, and digital health integration, though adoption lags in resource-limited regions. Demand-supply balance tilts toward supply constraints due to raw material shortages and production bottlenecks, particularly for high-complexity tests. Key risks include regulatory shifts, reimbursement pressures, and oversaturation in mature markets. Strategic partnerships and vertical integration are critical for sustaining growth in this dynamic landscape.

Key Insights for Decision-Makers3 items

Prioritize investments in AI-driven diagnostics and POCT expansion to align with innovation trends.

Mitigate supply chain risks by diversifying suppliers and adopting agile manufacturing practices.

Monitor regulatory developments in high-growth regions to preempt compliance challenges.

11 items

1. Executive Summary

2. IVD (In Vitro Diagnostic) Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global IVD (In Vitro Diagnostic) Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global IVD (In Vitro Diagnostic) Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Ambulatory Surgical Centers

6.1.3. Diagnostic Centers

6.1.4. Others

6.2. Global IVD (In Vitro Diagnostic) Testing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Instruments

6.2.2. Reagents

6.2.3. Data Management Software

6.2.4. Services

6.3. Global IVD (In Vitro Diagnostic) Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global IVD (In Vitro Diagnostic) Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global IVD (In Vitro Diagnostic) Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global IVD (In Vitro Diagnostic) Testing Market Competition by Key Manufacturers

8.1. Global IVD (In Vitro Diagnostic) Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global IVD (In Vitro Diagnostic) Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Siemens Healthineers

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. F. Hoffmann-La Roche

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Danaher (Beckman Coulter Inc)

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Abbott Laboratories

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Thermo Fisher Scientific

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global IVD (In Vitro Diagnostic) Testing Market

Figure 4: Global IVD (In Vitro Diagnostic) Testing Market: Drivers

Figure 5: Global IVD (In Vitro Diagnostic) Testing Market: Challenges

Figure 6: Global IVD (In Vitro Diagnostic) Testing Market: Trends

Figure 7: Global IVD (In Vitro Diagnostic) Testing Market: Opportunity

Figure 8: Global IVD (In Vitro Diagnostic) Testing Market: Restraint

Figure 9: Global IVD (In Vitro Diagnostic) Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global IVD (In Vitro Diagnostic) Testing Market Value (USD Million) By Region

Figure 15: Global IVD (In Vitro Diagnostic) Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global IVD (In Vitro Diagnostic) Testing Market Value (USD Million) By Region

Figure 23: Global IVD (In Vitro Diagnostic) Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

63 items

Table 1: Market Segmentation Analysis

Table 2: Global IVD (In Vitro Diagnostic) Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global IVD (In Vitro Diagnostic) Testing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global IVD (In Vitro Diagnostic) Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global IVD (In Vitro Diagnostic) Testing Market Value (USD Million) By Region

Table 10: Global IVD (In Vitro Diagnostic) Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global IVD (In Vitro Diagnostic) Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global IVD (In Vitro Diagnostic) Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global IVD (In Vitro Diagnostic) Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Siemens Healthineers Basic Information And Sales Area

Table 31: Siemens Healthineers. Products Portfolio

Table 32: F. Hoffmann-La Roche Basic Information And Sales Area

Table 33: F. Hoffmann-La Roche. Products Portfolio

Table 34: Danaher (Beckman Coulter Inc) Basic Information And Sales Area

Table 35: Danaher (Beckman Coulter Inc). Products Portfolio

Table 36: Abbott Laboratories Basic Information And Sales Area

Table 37: Abbott Laboratories. Products Portfolio

Table 38: Thermo Fisher Scientific Basic Information And Sales Area

Table 39: Thermo Fisher Scientific. Products Portfolio

Table 40: Global Market Value (USD Million) (2025-2032) By Application

Table 41: Global Market Share (%) By Application (2032)

Table 42: Global Market Value (USD Million) (2025-2032) By Types

Table 43: Global Market Share (%) By Types (2032)

Table 44: Global IVD (In Vitro Diagnostic) Testing Market Value (USD Million) By Region

Table 45: Global IVD (In Vitro Diagnostic) Testing Market Share (%) By Region (2025-2032)

Table 46: North America Market Value (USD Million) (2025-2032) By Country

Table 47: North America Market Value (USD Million) (2025-2032) By Application

Table 48: North America Market Value (USD Million) (2025-2032) By Types

Table 49: Europe Market Value (USD Million) (2025-2032) By Country

Table 50: Europe Market Value (USD Million) (2025-2032) By Application

Table 51: Europe Market Value (USD Million) (2025-2032) By Types

Table 52: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 53: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 55: South America Market Value (USD Million) (2025-2032) By Country

Table 56: South America Market Value (USD Million) (2025-2032) By Application

Table 57: South America Market Value (USD Million) (2025-2032) By Types

Table 58: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 59: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 61: Research Programs/Design For This Report

Table 62: Key Data Information From Secondary Sources

Table 63: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

IVD (In Vitro Diagnostic) Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	70.00 billion
Revenue forecast in 2033	122.08 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Siemens Healthineers; F. Hoffmann-La Roche; Danaher (Beckman Coulter Inc); Abbott Laboratories; Thermo Fisher Scientific
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options